GENinCode UK Ltd. (GENI) AI Stock Analysis

• Market Cap: £5.59M
• Dividend Yield: N/A
• Average Volume (3M): 1.99M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.42
• Revenue Growth: 12.12%
• EPS Growth: 54.24%
• Country: UK
• Employees: 42
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.01
• Shares Outstanding: 286,882,050
• 10 Day Avg. Volume: 166,671
• 30 Day Avg. Volume: 1,986,185
• PEG Ratio: 0.02
• Price to Book (P/B): 5.90
• Price to Sales (P/S): 2.46
• P/FCF Ratio: -1.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: 2.00p ▼(-9.09% Downside)

The score is held down primarily by weak financial performance (ongoing losses, negative operating cash flow, and declining equity). Technicals add pressure as the stock trades below major moving averages with negative MACD, while valuation is constrained by negative earnings and no dividend yield data.

Positive Factors

Revenue Growth

Mid-teens revenue growth indicates the business is expanding its testing volume and commercial adoption. Sustained top-line growth supports scale in lab operations and software subscriptions, improving the runway to reach break-even as fixed costs are spread over higher volumes.

Diversified Revenue Streams

Multiple revenue channels—clinical testing, hospital/clinic partnerships, pharma collaborations, and software licensing—provide structural resilience. Diversification reduces dependence on any single customer or product and supports recurring revenue as software and partnerships mature.

Low Leverage

A low-debt profile preserves financial flexibility during a transition to profitability and limits interest burden. With limited leverage, management can prioritize reinvestment, R&D, and strategic partnerships without high fixed financing costs that would strain cash flow.

Negative Factors

Persistent Net Losses

Ongoing net losses mean profitability remains distant; sustained operating deficits can erode capital and investor support. If structural cost items (labs, R&D, sales) are not reined in or margins improved, losses could continue despite revenue growth.

Negative Operating Cash Flow

Consistent negative operating cash flow forces dependence on external financing, increasing dilution or covenant risk. Over the medium term, inability to convert revenue growth into positive operating cash would threaten funding for labs, regulatory costs, and commercial expansion.

Fragile Equity Position

Declining shareholders' equity and historical negative equity signal balance-sheet vulnerability. This weak equity base limits the company's buffer against setbacks, reduces borrowing capacity on favorable terms, and raises the risk of dilution if capital raises become necessary.

GENinCode UK Ltd. Business Overview & Revenue Model

Company Description

GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.

How the Company Makes Money

GENinCode UK Ltd. generates revenue through multiple streams, primarily by providing genetic testing services to healthcare providers and patients. The company charges fees for its testing services, which can vary depending on the complexity and scope of the tests performed. Additionally, GENI earns income through partnerships with hospitals and clinics that incorporate its genetic testing into their patient care protocols. The company may also engage in collaborations with pharmaceutical firms for research and development initiatives, further enhancing its revenue through grants or shared revenue agreements. Furthermore, GENI's software solutions may include subscription fees or licensing agreements, contributing additional revenue to its overall earnings.

GENinCode UK Ltd. Financial Statement Overview

Summary

GENinCode UK Ltd. is facing ongoing financial challenges, characterized by persistent losses and cash flow constraints. While revenue growth is a positive sign, the company's inability to achieve profitability, coupled with declining equity and reliance on external financing, highlights significant risks.

Income Statement

The income statement reveals persistent challenges, with a series of net losses despite a steady increase in revenue from 2020 to 2024. The gross profit margin has shown improvement, but the net profit margin remains negative due to significant operating losses as evidenced by negative EBIT and EBITDA margins. The company is working on expanding its revenue base; however, profitability remains a challenge.

Balance Sheet

The balance sheet shows a decline in stockholders' equity over the years, with a negative equity encountered in 2019. While the company has maintained low levels of debt, the equity ratio has decreased significantly, indicating financial vulnerability. The return on equity is negative, reflecting ongoing losses.

Cash Flow

Cash flow analysis points to significant negative operating cash flows, indicating challenges in generating cash from operations. Although there has been improvement in free cash flow over the recent period, the overall trend remains negative. The company relies heavily on financing activities to support operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.91M	2.70M	2.16M	1.43M	1.15M	960.80K
Gross Profit	1.37M	1.43M	1.02M	632.00K	593.00K	523.02K
EBITDA	-4.78M	-4.69M	-6.65M	-5.57M	-4.10M	-1.03M
Net Income	-4.97M	-4.43M	-7.02M	-5.56M	-4.14M	-1.17M
Balance Sheet
Total Assets	4.22M	2.66M	4.19M	11.80M	15.21M	2.42M
Cash, Cash Equivalents and Short-Term Investments	2.50M	1.17M	2.53M	9.75M	14.56M	2.00M
Total Debt	191.00K	234.00K	299.00K	354.00K	0.00	0.00
Total Liabilities	1.56M	1.54M	2.90M	3.90M	1.49M	563.50K
Stockholders Equity	2.66M	1.13M	1.29M	7.90M	13.72M	1.86M
Cash Flow
Free Cash Flow	-4.99M	-5.22M	-7.54M	-4.61M	-3.17M	-1.11M
Operating Cash Flow	-4.95M	-5.17M	-7.51M	-3.76M	-3.02M	-1.04M
Investing Cash Flow	-23.00K	50.00K	136.00K	-849.00K	-145.00K	-68.27K
Financing Cash Flow	3.63M	3.65M	-94.00K	-47.00K	15.86M	3.03M

GENinCode UK Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GENI, the sentiment is Negative. The current price of 2.2 is below the 20-day moving average (MA) of 2.47, below the 50-day MA of 2.55, and below the 200-day MA of 2.35, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 37.80 is Neutral, neither overbought nor oversold. The STOCH value of 14.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GENI.

GENinCode UK Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRCI	58 Neutral	£11.35M	-0.31	-122.54%	―	-57.03%	-15.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CNSL	50 Neutral	£5.47M	4.04	13.26%	―	-10.20%	714.29%
PRM	46 Neutral	£9.45M	-2.83	―	―	12.19%	18.12%
ABDX	45 Neutral	£15.69M	-6.58	-90.48%	―	37.39%	-126.19%
GDR	44 Neutral	£9.01M	-0.94	-153.92%	―	90.42%	79.21%
GENI	41 Neutral	£5.59M	-0.84	-181.41%	―	12.12%	54.24%

GENinCode UK Ltd. Corporate Events

GENinCode Partners with Sohin Genetics to Distribute Heart Disease Risk Test in Mexico

GENinCode has announced a collaboration with Sohin Genetics in Mexico to distribute its CARDIO inCode-Score® test, a polygenic risk score for predicting and preventing coronary heart disease. This partnership aims to expand GENinCode’s reach in the Mexican market, where cardiovascular disease is a significant health concern, and to enhance the identification and prevention of heart disease through personalized treatment strategies, potentially reducing severe cardiovascular events and associated healthcare costs.

The most recent analyst rating on (GB:GENI) stock is a Hold with a £3.50 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.

GENinCode Partners with Thermo Fisher for CARDIO inCode-Score® Expansion

GENinCode UK Ltd. has announced a collaboration with Thermo Fisher Scientific to sell, distribute, and manufacture its CARDIO inCode-Score® test, which predicts genetic risk for coronary heart disease. This partnership aims to expand the test’s availability across the US and EMEA regions, leveraging Thermo Fisher’s manufacturing capabilities and distribution network. The collaboration is expected to enhance GENinCode’s market presence and accelerate the adoption of its test, which has already received New York State licensure and is included in the US Clinical Laboratory Fee Schedule. The move is part of GENinCode’s broader strategy to expand its commercial footprint and improve public health outcomes by integrating genetic risk assessments into clinical pathways.

The most recent analyst rating on (GB:GENI) stock is a Sell with a £2.00 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.

GENinCode’s CARDIO inCode-Score® Test Gains New York State Approval

GENinCode UK Ltd. has announced the approval of its CARDIO inCode-Score® test by the New York State Department of Health, enabling full state coverage under the US Centers for Medicare and Medicaid Services. This approval allows the company to collect patient samples from New York State for testing at its California lab, marking a significant step in its US market expansion. The test, which predicts genetic risk for heart disease, is expected to enhance preventive healthcare strategies and reduce the economic burden of cardiovascular diseases. The approval also supports GENinCode’s ongoing discussions with the FDA for further market penetration.

The most recent analyst rating on (GB:GENI) stock is a Sell with a £2.00 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.

GENinCode’s CARDIO inCode-Score® Validated for Enhanced Heart Disease Risk Prediction

GENinCode Plc has announced the publication of a significant clinical study in JACC: Advances, which validates the company’s CARDIO inCode-Score® Polygenic Risk Score for predicting coronary heart disease risk. The study, conducted by Kaiser Permanente, found that genetic risk significantly modifies the relationship between LDL-cholesterol and coronary heart disease, suggesting that integrating genetic data with clinical assessments can revolutionize cardiovascular risk stratification and prevention. This approach could lead to earlier interventions for at-risk populations, potentially improving public health outcomes and reducing the economic burden of long-term heart disease care.

The most recent analyst rating on (GB:GENI) stock is a Hold with a £4.00 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.